Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.

T.S. Waddell, I. Chau, C. Peckitt, D. Gonzalez, A. Wotherspoon, B. Patel, G.W. Middleton, J. Wadsley, D. Ferry, W. Mansoor, T.D.L. Crosby, F.Y. Coxon, D. Smith, J.S. Waters, T. Iveson, S. Falk, S. Slater, A.F.C. Okines, D. Cunningham

Research output: Contribution to conferenceOtherpeer-review

Cite this